Cheer­ful mid-stage de­pres­sion drug da­ta send Ax­some stock fly­ing

On the same day Sage rolled out $SAGE tremen­dous oral drug da­ta in post­par­tum de­pres­sion, Ax­some Ther­a­peu­tics has an­nounced that its lead ex­per­i­men­tal CNS drug in­duced sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ments in pa­tients with ma­jor de­pres­sive dis­or­der (MDD) in a mid-stage study, prompt­ing the com­pa­ny’s stock $AXSM to sky­rock­et more than 150% in pre-mar­ket trad­ing on Mon­day.

In gen­er­al, tri­als test­ing de­pres­sion drugs are no­to­ri­ous­ly tricky and prone to fail­ure, in ma­jor part due to high rates of the place­bo ef­fect.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER